actin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-06. Anything still debated is marked as such rather than presented as settled.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
=== PE Biosystems === In 1998, PE Applied Biosystems became PE Biosystems, and the division's revenues reached US$921.8 million. In January 1998 Perkin-Elmer acquired PerSeptive Biosystems (formerly of Framingham, Massachusetts. It was a leader in the bio-instrumentation field where it made biomolecule purification systems for protein analysis. Noubar Afeyan, Ph.D., had been the founder, chairman, and CEO of PerSeptive, and with the Perkin-Elmer successor company he set up the later tracking stock for Celera. In 1998, Perkin-Elmer formed the PE Biosystems division, by consolidating Applied Biosystems, PerSeptive Biosystems, Tropix and PE Informatics. Informatics was formed from the Perkin-Elmer combination of two other acquisitions, Molecular Informatics and Nelson Analytical Systems, with existing units of Perkin-Elmer. While planning the next new generation of machines, PE Biosystems' president, Michael W. Hunkapiller, calculated that it would be possible for their own private industry to decode the human genome before the academic consortium could complete it, by using the resources of a single, industrial-scale center, even though it would require starting from scratch. It was a bold prediction, given that the consortium target date set by Dr. Watson back in 1990 had been the forward year of 2005, only seven years away, and with the consortium already half the way to the completion target date. Also, it meant that Dr.
=== Legal status === Icatibant received orphan drug status in Australia, the EU, Switzerland, and the US for the treatment of hereditary angioedema (HAE). In the EU, the approval by the European Commission (July 2008) allows Jerini to market Firazyr in the European Union's 27 member states, as well as Switzerland, Liechtenstein and Iceland, making it the first product to be approved in all EU countries for the treatment of hereditary angioedema. In the US, the drug was granted FDA approval in August 2011.
in situ (of a scientific experiment or biological process) Occurring or made to occur in a natural, uncontrolled setting, or in the natural or original position or place, as opposed to in a foreign cell or tissue type or in an artificial environment.
troops fighting in Vietnam "remains one of our few bargaining weapons". In the same memo, Kissinger stated he was "deeply disturbed" that Nixon had started pulling out U.S. troops, saying that withdrawing the troops was like "salted peanuts" to the American people ("The more U.S troops come home, the more will be demanded"), giving the advantage to the enemy who merely had to "wait us out". Instead, he recommenced that the United States resume bombing North Vietnam and mine the coast. Later in September 1969, Kissinger proposed a plan for what he called a "savage, punishing" blow against North Vietnam code-named Duck Hook to Nixon, arguing that this was the best way to force North Vietnam to agree to peace on American terms. Laird was strongly opposed to Duck Hook, warning Nixon that the use of nuclear weapons to kill a massive number of North Vietnamese civilians would alienate American public opinion from the administration and persuaded Nixon to reject it. Reflecting his background as a Harvard professor of political science who belonged to the Primat der Aussenpolitik school, which saw foreign policy as belonging only to a small elite, Kissinger was less sensitive to public opinion than Laird, a former Republican congressman who constantly advised Nixon to keep American public opinion in mind. Laird used the National Moratorium protests of 15 November 1969 to persuade Nixon to cancel Duck Hook, arguing that if the war as it was had caused the largest demonstrations ever in American history, then Kissinger's plans for Duck Hook would alienate the public even more.
Sources: en.wikipedia.org
== Metabolism == The kinin–kallikrein system makes bradykinin by proteolytic cleavage of its kininogen precursor, high-molecular-weight kininogen (HMWK or HK), by the enzyme kallikrein. Moreover, there is evidence that plasmin, a fibrinolytic enzyme, is able to generate bradykinin after HMWK cleavage. In humans, bradykinin is broken down by many different kininases: angiotensin-converting enzyme (ACE, kininase II), neprilysin, NEP2, aminopeptidase P (APP), carboxypeptidase N (CPN, kininase I), Carboxypeptidase M, Neutral endopeptidase 24.15, Endothelin converting enzyme-1, Endothelin converting enzyme-2.
=== March === 3 March – The GMB and Unison unions have called off ambulance strikes in England scheduled for 6 and 8 March after the UK government agrees to reopen talks on pay for the 2022–23 and 2023–24 financial years. Following a trial at Luton Crown Court, four people are jailed for their part in a robbery that went wrong during which their victim, Saul Murray, was stabbed after being given the drug GHB in an attempt to knock him out. Ikem Affia is sentenced to life imprisonment for murder, with a minimum of 25 years, while the three other gang members are given lesser sentences for manslaughter. The gang were caught after one of them was captured on CCTV wearing a rare Moncler coat worth £1,000, of which only 69 had been sold in the UK. 5 March – The Unite union calls off ambulance strikes scheduled for 6 and 8 March. 8 March – The National Institute for Health and Care Excellence (NICE) approves the use of the weight loss drug semaglutide (marketed as Wegovy) by the NHS in England. 13 March – The Unite union calls off a planned strike by bus drivers at National Express West Midlands scheduled for 16 March after receiving a revised pay offer, which is to be put to members. 16 March – NHS staff in England, including nurses and ambulance staff, are offered a 5% pay rise from April along with a one-off payment of £1,655 to cover backdated pay. The offer does not include doctors, who are on a different contract.
==== Glycopeptide-type CSP ==== Armstrong introduced macrocyclic glycopeptides (also known as glycopeptide antibiotics) as a new class of chiral selector for liquid chromatography in 1994. At present, vancomycin, teicoplanin and ristocetin are available under the brand names Chirobiotic V, Chirobiotic T and Chirobiotic R respectively. These cyclic glycopeptides have multiple chiral centers and a cup-like inclusion area to which a floating sugar lid is attached. Similar to protein chiral selectors, the amphoteric cyclic glycopeptides consist of peptide and carbohydrate binding sites leading to possibilities for different modes of interaction beside the formation of inclusion complexation. In this chiral selector the cavities are shallower than that of CDs and hence the interactions are weaker, allows more rapid solute exchange between phases, higher column efficiency. operates in normal phase, reversed-phase and polar organic phase. The complex structural nature of glycopeptide antibiotic class of CSP has made the understanding of the mechanism of chiral recognition at molecular level tricky. For instance, vancomycin molecule has 18 stereogenic centers in the molecule and offers a complex cyclodextrin-like chiral environment. In comparison to a single basket of cyclodextrins, vancomycin consists of three baskets, resulting in a more complex inclusion of appropriate guest molecules. The attractive forces include π-π interactions, hydrogen bonding, ionic interactions, and dipole stacking.
In contrast, eukaryotes generally have many copies of the rRNA genes organized in tandem repeats. In humans, approximately 300–400 repeats are present in five clusters, located on chromosomes 13 (RNR1), 14 (RNR2), 15 (RNR3), 21 (RNR4) and 22 (RNR5). Diploid humans have 10 clusters of genomic rDNA which in total make up less than 0.5% of the human genome. It was previously accepted that repeat rDNA sequences were identical and served as redundancies or failsafes to account for natural replication errors and point mutations. However, sequence variation in rDNA (and subsequently rRNA) in humans across multiple chromosomes has been observed, both within and between human individuals. Many of these variations are palindromic sequences and potential errors due to replication. Certain variants are also expressed in a tissue-specific manner in mice. Mammalian cells have 2 mitochondrial (12S and 16S) rRNA molecules and 4 types of cytoplasmic rRNA (the 28S, 5.8S, 18S, and 5S subunits). The 28S, 5.8S, and 18S rRNAs are encoded by a single transcription unit (45S) separated by 2 internally transcribed spacers. The first spacer corresponds to the one found in bacteria and archaea, and the other spacer is an insertion into what was the 23S rRNA in prokaryotes. The 45S rDNA is organized into 5 clusters (each has 30–40 repeats) on chromosomes 13, 14, 15, 21, and 22. These are transcribed by RNA polymerase I. The DNA for the 5S subunit occurs in tandem arrays (~200–300 true 5S genes and many dispersed pseudogenes), the largest one on the chromosome 1q41-42.
== Sample preparation == A rule-of-thumb is that any molecule that will dissolve in methanol or a less polar solvent is compatible with SFC, including non-volatile polar solutes. CO2 has polarity similar to n-heptane at its critical point. The solvent's elution strength can be increased just by increasing density or alternatively, using a polar co-solvent. In practice, when the fraction of the co-solvent is high, the mobile phase might not be truly at supercritical fluid state, but this terminology is used regardless, and the chromatograms show better elution and higher efficiency nevertheless.
Sources: en.wikipedia.org
== External links == True Anatomy for New Ways of Teaching von Hagens Plastination offers one-of-a-kind, real human teaching specimens! Plastination technique, on Body Worlds page Plastination website by Dr. Selcuk Tunali Laboratory of Plastination & Anatomical Techniques, Universidad de La Frontera, Temuco, Chile (Dr. Nicolas E. Ottone) Plastination Models Inc. Plastination in India by Dr. N. M. Shama Sundar. Plastination: Silicone Impregnation of Specimens (the standard S10 technique) Plastination: The Sheet Plastination Technique International Society for Plastination The New Plastination Index Online The New Plastination Index on-line: Subject Index "Exhibit Human" a documentary on plastination by Aaron Edell Learn About PCOM's Plastination Process Plastination
== History == Historical descriptions of possible PMOS symptoms date to ancient Greece, where Hippocrates described women with "thick, oily skin and absence of menstruation." The earliest known description of what is now recognized as PMOS dates from 1721 in Italy, which described "Young married peasant women, moderately obese and infertile, with two larger than normal ovaries, bumpy, shiny and whitish, just like pigeon eggs". Polycystic ovaries were likely first formally described in 1844 by the French doctor Achille Chereau. In 1935, American gynecologists Irving F. Stein and Michael L. Leventhal published a report linking polycystic ovaries to hirsutism, infertility, and lack of periods. The report also hypothesised that PMOS results from endocrine dysfunction, initiating research into its hormonal causes and giving rise to the term Stein–Leventhal syndrome. By the 1980s, the metabolic side of PMOS started to be studied, before the start of genetics research in the 1990s.
The chemical names were based on the side chains of the compounds. In 1948, Chain introduced the chemical names as standard nomenclature, remarking that this would "make the nomenclature as far as possible unambiguous". In Kundl, Tyrol, Austria, in 1952, Hans Margreiter and Ernst Brandl of Biochemie developed the first acid-stable penicillin for oral administration, penicillin V. American chemist John C. Sheehan at the Massachusetts Institute of Technology (MIT) completed the first chemical synthesis of penicillin V in 1957. Sheehan had started his studies into penicillin synthesis in 1948, and during these investigations developed new methods for the synthesis of peptides, as well as new protecting groups—groups that mask the reactivity of certain functional groups. Although the initial synthesis developed by Sheehan was not appropriate for mass production of penicillins, one of the intermediate compounds in Sheehan's synthesis was 6-aminopenicillanic acid (6-APA), the nucleus of penicillin. An important development was the discovery of 6-APA itself. In 1957, researchers at the Beecham Research Laboratories in Surrey isolated 6-APA from the culture media of P. chrysogenum. 6-APA was found to constitute the core nucleus of penicillin (and subsequently many β-lactam antibiotics) and was easily chemically modified by attaching side chains through chemical reactions. The discovery was published in Nature in 1959. This paved the way for new and improved drugs as all semisynthetic penicillins are produced from chemical manipulation of 6-APA.
Automation inherent in precision agriculture, from "milking robots on dairy farms to greenhouses with automated climate control," can make crop and livestock management more efficient by reducing required labor.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.